We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0JQ2 market cap is 41.47M. The company's latest EPS is USD -15.6699 and P/E is -0.41.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 6.07M | 6.36M | 17.05M | 4.18M | 230k |
| Operating Income | -88.22M | -96.23M | -130.25M | -81.71M | -39.66M |
| Net Income | -94.35M | -104.33M | -142.61M | -44.82M | -42.2M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 154.32M | 221.61M | 139.43M | 86.82M | 55.95M |
| Total Liabilities | 124.63M | 121.61M | 122.62M | 67.85M | 48.45M |
| Total Equity | 29.69M | 100M | 16.8M | 18.97M | 7.5M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -92.72M | -90.69M | -108.24M | -78.91M | -27.93M |
| Investing | -1.34M | -78.21M | 70.8M | 62.72M | -429k |
| Financing | 8.98M | 160.63M | 42.55M | -7.94M | 8.51M |
| Market Cap | 41.47M |
| Price to Earnings Ratio | -0.41 |
| Price to Sales Ratio | 74.36 |
| Price to Cash Ratio | 0.34 |
| Price to Book Ratio | 2.28 |
| Dividend Yield | - |
| Shares Outstanding | 2.69M |
| Average Volume (1 week) | 148 |
| Average Volume (1 Month) | 228 |
| 52 Week Change | 0.00% |
| 52 Week High | 15.40 |
| 52 Week Low | 15.40 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Kala Pharmaceuticals Inc |
| Address |
corporation trust center watertown, massachusetts 19801 |
| Website | https://www.kalarx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
